Boundless Bio (BOLD) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Boundless Bio (BOLD) has outperformed LeonaBio (LONA) over the past year, gaining 98.5% versus a gain of 45.9%. Boundless Bio is the larger company by market cap ($57.6 million vs $54.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | LONA |
|---|---|---|
| Share price | $2.53 | $5.75 |
| Market cap | $57.55M | $54.17M |
| 1-day change | -1.94% | 0.00% |
| YTD return | +115.00% | -24.04% |
| 1-year return | +98.46% | +45.94% |
| 5-year return | — | -93.99% |
| EPS (TTM) | $-2.85 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $14.21 |
| 52-week low | $0.961 | $2.21 |
| Distance from 52-week high | -20.04% | -59.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +58.10% | +201.39% |
| Average volume | 182.04K | 185.45K |
| Shares outstanding | 22.75M | 9.42M |
| Employees | 28 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed LONA by 52.5 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
BOLD vs LONA FAQ
Which is bigger, Boundless Bio or LeonaBio?
Boundless Bio (BOLD) is larger, with a market capitalization of $57.55M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, BOLD or LONA?
BOLD returned +98.46% over the past 12 months, compared with +45.94% for LONA (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and LeonaBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Boundless Bio and Biotechnology: Biological Products (No Diagnostic Substances) for LeonaBio.